Syngene International has released its audited financial results for the quarter and year ended March 31, 2026. The company reported a standalone annual revenue of Rs. 34,238 million and a consolidated annual revenue of Rs. 37,387 million. Alongside its financial disclosures, the company declared a final dividend of Rs. 1.25 per equity share and announced the appointment of M/s S. R. Batliboi & Associates LLP as its new statutory auditors for a five-year term.
Financial Performance Overview
For the financial year ended March 31, 2026, Syngene International demonstrated consistent operational performance. On a consolidated basis, the company achieved an annual revenue from operations of Rs. 37,387 million, compared to Rs. 36,424 million in the previous year. The consolidated profit for the year stood at Rs. 3,167 million. On a standalone basis, annual revenue reached Rs. 34,238 million with a net profit of Rs. 3,049 million.
Dividend and Governance Updates
The Board of Directors has recommended a final dividend of Rs. 1.25 per equity share (face value of Rs. 10/-) for the financial year 2025-26. Shareholders can expect the dividend to be processed following approval at the upcoming Annual General Meeting, which is scheduled for July 29, 2026. The record date for determining eligibility for the dividend has been fixed as June 26, 2026.
Appointment of Statutory Auditors
In a move to strengthen corporate oversight, the company has approved the appointment of M/s S. R. Batliboi & Associates LLP as its new statutory auditors. This appointment is for a term of 5 years, commencing from the conclusion of the 33rd Annual General Meeting in July 2026 and continuing until the conclusion of the meeting to be held in 2031, subject to approval from the shareholders.
Strategic Developments
The company continues to advance its infrastructure and operational capabilities. Notably, the firm has accounted for significant capital investments, including the integration of a biologics manufacturing site and license acquisitions for new production lines. These efforts are part of a broader strategy to enhance capacity for large-molecule services across the Group’s global network. Management also confirmed the payment of managerial remuneration to Executive Chairperson Ms. Kiran Mazumdar-Shaw as part of the board-approved miscellaneous resolutions.
Source: BSE
